Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Nitisinone tablets bulk supplier for pharma manufacturers

Nitisinone Tablets 2 mg and 5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 2 mg and 5 mg

Reference Brands: Orfadin®

Category: Orphan Drugs

Nitisinone inhibits the enzyme 4-hydroxyphenylpyruvate dioxygenase, reducing the production of toxic metabolites in hereditary tyrosinemia type 1 (HT-1). Benefits include preventing liver and kidney damage, decreasing hypersensitivity reactions, and improving survival rates in HT-1 patients by controlling disease progression.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Nitisinone Tablets? List it or send an offer →

Product Description: Nitisinone inhibits the enzyme 4-hydroxyphenylpyruvate dioxygenase, reducing the production of toxic metabolites in hereditary tyrosinemia type 1 (HT-1). Benefits include preventing liver and kidney damage, decreasing hypersensitivity reactions, and improving survival rates in HT-1 patients by controlling disease progression.

Nitisinone Tablets — third party manufacturing & bulk supply

Nitisinone Tablets 2 mg and 5 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Nitisinone Tablets is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Nitisinone Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Nitisinone Tablets →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Nitisinone tablets is listed as Tablets in 2 mg and 5 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Nitisinone tablets is referenced against Orfadin®. Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Treprostinil IV

Strength:
2 mg (0.1 mg/mL), 4 mg (0.2 mg/mL), 8 mg (0.4 mg/mL), 20 mg (1 mg/mL), 50 mg (2.5 mg/mL), 100 mg (5 mg/mL), 200 mg (10 mg/mL), or 400 mg (20 mg/mL)

Form: SC or Intravenous (IV)

Reference Brands: Remodulin(US & EU)

View Details
Alglucosidase Alfa IV

Strength:
50 mg/vial

Form: Lyophilized powder

Reference Brands: Lumizyme®(US & EU)

View Details
Iloprost Inahalation Solution

Strength:
10 mcg/mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Ventavis®(EU & US)

View Details
Galsulfase IV

Strength:
1mg/ml

Form: Lyophilized powder for IV

Reference Brands: -

View Details
Taliglucerase Alfa

Strength:
200U

Form: Injection

Reference Brands: Elelyso (USA/EU)

View Details
Agalsidase Beta

Strength:
35 mg

Form: Injection

Reference Brands: Fabrazyme (USA/EU)

View Details
Migalastat Hydrochloride

Strength:
123 mg

Form: Capsules

Reference Brands: Galafold (USA/EU)

View Details
Emapalumab-Lzsg

Strength:
10 mg/2 mL, 50 mg/10 mL

Form: Injection

Reference Brands: Gamifant (USA/EU)

View Details
Enquire Now

Usually answered within 48 hours | GMP documents shared before you commit

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us